This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Lilly (LLY) Has Outperformed the Industry This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.
Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab
by Zacks Equity Research
The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US
by Zacks Equity Research
With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
by Zacks Equity Research
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA
by Zacks Equity Research
Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
by Zacks Equity Research
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
by Zacks Equity Research
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
by Zacks Equity Research
Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.
Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong
by Zacks Equity Research
Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -68.06% and -0.99%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More
by Kinjel Shah
Let us take a look at four big drug/biotech companies, REGN, BMY, INCY & ZTS, which are gearing up for their earnings release.
Incyte Corp (INCY) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Incyte Corp (INCY) has been struggling lately, but the selling pressure may be coming to an end soon.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Incyte (INCY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.
Stock Market News for Oct 7, 2020
by Zacks Equity Research
Benchmarks closed sharply lower on Tuesday after President Donald Trump said he would halt coronavirus stimulus negotiations until after the Presidential elections next month.